Zentalis Pharmaceuticals, Inc. Research and Development Expense
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Research and Development Expense of $35.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Zentalis Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-06-30 was $35.16M, a 27.36% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-03-31 was $28.72M, a 5.39% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-12-31 was $29.49M, a 10.57% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-09-30 was $22.95M, a 37.68% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. research and development expense for fiscal 2025 was $107.30M, a 36.05% decline from fiscal 2024.
- Zentalis Pharmaceuticals, Inc. research and development expense for fiscal 2024 was $167.77M, a 11.51% decline from fiscal 2023.
- Zentalis Pharmaceuticals, Inc. research and development expense for fiscal 2023 was $189.59M, a 9.76% increase from fiscal 2022.
- Zentalis Pharmaceuticals, Inc. research and development expense for fiscal 2022 was $172.73M, a 1.63% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $35.16M 10-Q · filed 2026-08-06 | $63.88M 10-Q · filed 2026-08-06 | $93.37M derived: sum of 3 quarters · filed 2026-08-06 | $116.32M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $28.72M 10-Q · filed 2026-05-12 | $58.20M derived: sum of 2 quarters · filed 2026-05-12 | $81.15M derived: sum of 3 quarters · filed 2026-05-12 | $108.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $29.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $52.44M derived: sum of 2 quarters · filed 2026-03-26 | $80.05M derived: sum of 3 quarters · filed 2026-08-06 | $107.30M 10-K · filed 2026-03-26 |
| 2025-09-30 | $22.95M 10-Q · filed 2025-11-10 | $50.56M derived: sum of 2 quarters · filed 2026-08-06 | $77.81M 10-Q · filed 2025-11-10 | $110.78M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $27.61M 10-Q · filed 2026-08-06 | $54.86M 10-Q · filed 2026-08-06 | $87.83M derived: sum of 3 quarters · filed 2026-08-06 | $124.65M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $27.25M 10-Q · filed 2026-05-12 | $60.22M derived: sum of 2 quarters · filed 2026-05-12 | $97.04M derived: sum of 3 quarters · filed 2026-05-12 | $145.43M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $32.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $69.80M derived: sum of 2 quarters · filed 2026-03-26 | $118.18M derived: sum of 3 quarters · filed 2026-03-26 | $167.77M 10-K · filed 2026-03-26 |
| 2024-09-30 | $36.82M 10-Q · filed 2025-11-10 | $85.21M derived: sum of 2 quarters · filed 2025-11-10 | $134.79M 10-Q · filed 2025-11-10 | $186.35M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-06-30 | $48.39M 10-Q · filed 2025-08-06 | $97.97M 10-Q · filed 2025-08-06 | $149.53M derived: sum of 3 quarters · filed 2026-03-26 | $196.29M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-03-31 | $49.59M 10-Q · filed 2025-05-14 | $101.14M derived: sum of 2 quarters · filed 2026-03-26 | $147.91M derived: sum of 3 quarters · filed 2026-03-26 | $190.59M derived: sum of 4 quarters · filed 2026-03-26 |
| 2023-12-31 | $51.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $98.32M derived: sum of 2 quarters · filed 2026-03-26 | $141.01M derived: sum of 3 quarters · filed 2026-03-26 | $189.59M 10-K · filed 2026-03-26 |
| 2023-09-30 | $46.77M 10-Q · filed 2024-11-12 | $89.45M derived: sum of 2 quarters · filed 2024-11-12 | $138.03M 10-Q · filed 2024-11-12 | $178.65M derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-06-30 | $42.68M 10-Q · filed 2024-08-09 | $91.27M 10-Q · filed 2024-08-09 | $131.88M derived: sum of 3 quarters · filed 2025-03-26 | $174.06M derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-03-31 | $48.58M 10-Q · filed 2024-05-07 | $89.20M derived: sum of 2 quarters · filed 2025-03-26 | $131.38M derived: sum of 3 quarters · filed 2025-03-26 | $175.21M derived: sum of 4 quarters · filed 2025-03-26 |
| 2022-12-31 | $40.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $82.80M derived: sum of 2 quarters · filed 2025-03-26 | $126.62M derived: sum of 3 quarters · filed 2025-03-26 | $172.73M 10-K · filed 2025-03-26 |
| 2022-09-30 | $42.18M 10-Q · filed 2023-11-06 | $86.01M derived: sum of 2 quarters · filed 2023-11-06 | $132.12M 10-Q · filed 2023-11-06 | $170.56M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $43.83M 10-Q · filed 2023-08-09 | $89.94M 10-Q · filed 2023-08-09 | $128.38M derived: sum of 3 quarters · filed 2023-08-09 | $182.37M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $46.11M 10-Q · filed 2023-05-10 | $84.55M derived: sum of 2 quarters · filed 2023-05-10 | $138.55M derived: sum of 3 quarters · filed 2023-05-10 | $183.32M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $38.44M 10-K · filed 2022-02-24 | $92.44M derived: sum of 2 quarters · filed 2022-11-09 | $137.21M derived: sum of 3 quarters · filed 2022-11-09 | $175.60M 10-K · filed 2024-02-27 |
| 2021-09-30 | $54.00M 10-Q · filed 2022-11-09 | $98.77M derived: sum of 2 quarters · filed 2022-11-09 | $137.16M 10-Q · filed 2022-11-09 | $166.68M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $44.77M 10-Q · filed 2022-08-09 | $83.16M 10-Q · filed 2022-08-09 | $112.69M derived: sum of 3 quarters · filed 2022-08-09 | $137.35M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $38.39M 10-Q · filed 2022-05-05 | $67.92M derived: sum of 2 quarters · filed 2022-05-05 | $92.58M derived: sum of 3 quarters · filed 2022-05-05 | $110.04M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $29.52M 10-K · filed 2022-02-24 | $54.19M derived: sum of 2 quarters · filed 2022-02-24 | $71.64M derived: sum of 3 quarters · filed 2022-02-24 | $84.90M 10-K · filed 2023-03-01 |
| 2020-09-30 | $24.67M 10-K · filed 2022-02-24 | $42.12M derived: sum of 2 quarters · filed 2022-02-24 | $55.38M 10-Q · filed 2021-11-10 | $67.25M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $17.45M 10-K · filed 2022-02-24 | $30.71M 10-Q · filed 2021-08-12 | $42.58M derived: sum of 3 quarters · filed 2022-02-24 | $53.32M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $13.26M 10-K · filed 2022-02-24 | $25.13M derived: sum of 2 quarters · filed 2022-02-24 | $35.87M derived: sum of 3 quarters · filed 2022-02-24 | $44.55M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $11.87M 10-K · filed 2021-03-25 | $22.61M derived: sum of 2 quarters · filed 2021-03-25 | $31.30M derived: sum of 3 quarters · filed 2021-03-25 | $38.39M 10-K · filed 2022-02-24 |
| 2019-09-30 | $10.74M 10-K · filed 2021-03-25 | $19.43M derived: sum of 2 quarters · filed 2021-03-25 | $26.52M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $8.69M 10-K · filed 2021-03-25 | $15.78M 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | $7.09M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |